---
title: Reduce medication resistant motor symptoms
nct_id: NCT07371338
phase: PHASE1
status: RECRUITING
sponsor: Innopeutics Corporation
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07371338"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07371338"
last_fetched: "2026-05-10T14:02:45.616Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce medication resistant motor symptoms

**Goal (in five words):** Reduce medication resistant motor symptoms

**Official Title:** Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy

**Trial ID:** [NCT07371338](https://clinicaltrials.gov/study/NCT07371338)

## Key Facts

- **Phase:** PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Innopeutics Corporation
- **Target Enrollment:** 6 participants
- **Start Date:** 2026-05-30
- **Completion Date:** 2027-10-31
- **Conditions:** Parkinson Disease, Parkinson's Disease
- **Interventions:** IPS101A
- **Intervention Types:** DRUG

## Summary For Families

The goal is to help people with very advanced Parkinson's, whose symptoms stay uncontrolled despite all available medicines, by testing whether a gene therapy can safely improve motor function and reduce medication-resistant problems. IPS101A uses an adeno-associated virus to deliver a gene into brain cells so they can produce a protein or enzyme that boosts or normalizes local dopamine signaling, which may change how levodopa works or reduce the need for higher doses, and effects and safety will be closely monitored. The early phase, dose-escalation study plans to enroll up to six people aged 50 to 80 who have had Parkinson's for at least 10 years, are Hoehn and Yahr stage 4 or 5 off meds, and whose symptoms remain uncontrolled; people with Parkinson's disease dementia, major visual hallucinations, parkinsonism-plus syndromes, or drug-induced parkinsonism are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
2. Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
3. Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
4. Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
5. Subjects with a Hoehn \& Yahr stage of 4 or 5 in the off state at the Screening Visit.

Exclusion Criteria:

1. Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
2. Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
3. Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
4. Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
5. Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
6. Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.
```

## Locations (1)

- Severance Hospital, Seoul, South Korea _(37.5660, 126.9784)_
  - Professor, MD, PhD — (CONTACT) — phlee@yuhs.ac

## Central Contacts

- ChoLong Park — (CONTACT) — +82-2-3499-4266 — clpark@innopeutics.com
- Tae-gyun Kim — (CONTACT) — contact@innopeutics.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07371338*  
*HTML version: https://parkinsonspathways.com/trial/NCT07371338*  
*Source data: https://clinicaltrials.gov/study/NCT07371338*